Arum Therapeutics applies its strengths in medicinal chemistry to develop new anticancer agents to overcome current drug resistance using a platform for synthetic lethality (SL) target associated with the DNA damage response (DDR) mechanisms.

• Built and implemented the strategy for Novartis antimalarial drug discovery program • Worked with and managed a group of over 25 scientists both internally and across multiple external research sites• Developed new drug candidates for relapsing vivax malaria (KDU691 and LMV599) to preclinical development that target the developing liver stages of the parasite. • Identified new malaria drug targets, Plasmodium lysyl-tRNA synthetase and PI4 kinase, the latter of which has been recently validated in the clinic• The program developed and implemented novel assays to identify new chemical starting points for drugs that are fast acting (ring stage assay) or have the potential to target other parasite life stages, including dormant forms of P. vivax-type malaria• Implemented an innovative process of prioritizing chemical hits from high-throughput screening based on their activity across multiple assays and drug resistant strains to identify compounds with the potential to act through new mechanisms of action• Worked to build an extensive network of partnerships with external research labs and academics groups to bring in new tools and technologies to continually evolve the way we carry out malaria drug discovery.

• Project team head on antimalarial project. Lead an international, multidisciplinary team of scientists from lead declaration to preclinical development of the spiroindolone class of antimalarials (NITD609)• Lead chemist and deputy project team head for the development of dihydrofolate reductase (DHFR) inhibitors for the treatment of multi-drug resistance falciparum malaria• Concurrently managed multiple collaborations with CROs to support research projects.

• Team member of phosphatidylinositol-3 kinase (PI3K) project that lead to a development candidate (XL765) currently in Phase Ib/2 trials.• Design and synthesis of kinase inhibitors for use as anti-cancer agents• Supervised an associate research scientist

Synthesis and screening of a library of DNA binding agents based on analogs of distamycin APreparation of heterocyclic monomer building blocks for a library of DNA binding agentsSynthesis of isochrysohermidin-distamycin hybrids as new DNA binding agents